Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) Invested Capital (2023 - 2025)

Compass Therapeutics' Invested Capital history spans 3 years, with the latest figure at $196.8 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 57.14% year-over-year to $196.8 million; the TTM value through Dec 2025 reached $196.8 million, up 57.14%, while the annual FY2025 figure was $196.8 million, 57.14% up from the prior year.
  • Invested Capital for Q4 2025 was $196.8 million at Compass Therapeutics, down from $209.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $209.6 million in Q3 2025 and bottomed at $93.2 million in Q2 2025.
  • The 3-year median for Invested Capital is $152.8 million (2023), against an average of $152.4 million.
  • The largest YoY upside for Invested Capital was 57.14% in 2025 against a maximum downside of 36.21% in 2025.
  • A 3-year view of Invested Capital shows it stood at $148.5 million in 2023, then dropped by 15.69% to $125.2 million in 2024, then soared by 57.14% to $196.8 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Invested Capital are $196.8 million (Q4 2025), $209.6 million (Q3 2025), and $93.2 million (Q2 2025).